Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis B Vaccinated Children Not At Increased Risk Of MS
The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS). The study based in France involved 349 children with MS and 2,941 children without the disease. The children were all under the

Drug Watch: Agents in late-stage development for the treatment of hepatitis B and C virus infections (October 2008) (PDF)
Extract not available.

Biolex Therapeutics Completes $60 Million Series D Financing To Accelerate Development Of Locteron In Hepatitis C
Extract not available.

UPDATES AND COMMENTARY RSS Feed

Medical Device Boasts Encouraging Data for Hepatitis C Treatment
A medical device designed to clear viruses and immunosuppressive proteins from the blood reduced Hepatitis C viral load for several people on dialysis. Further case studies will determine if the Aethlon Hemopurifier® can induce a rapid virological response against Hepatitis...

Hepatitis C Study Increases Interest in SCV-07
Trial results show SciClone's SCV-07 effectively reduces Hepatitis C viral load in previous non-responders with genotype 1. Based on these encouraging results, a follow-up study to evaluate SCV-07's potential to replace or improve the current Hepatitis C standard treatment will...

New Hope for HCV
Funded by Pfizer, Tacere's licensed RNAi technology could change the way Hepatitis C is treated. A mechanism that inhibits genes from transferring information and creating new genetic material, RNAi-based drugs may be able to silence the genes that cause disease....

Evaluation of Assays for Antibody to Hepatitis E Virus by a Serum Panel

table  6.   Overall Performance of 12 Tests for Antibody to HEV
Test Overall Sensitivity* Limit of Detection by Endpoint Dilutiondagger Overall SpecificityDagger
1 44 (96) 1:80 45 (98)
2 45 (98) 1:160 57 (93)
3 45 (98) 1:20 48 (79)
4 38 (83) 1:10 60 (98)
5 41 (89) 1:20 61 (100)
6 31 (67) 1:40 61 (100)
7 42 (91) 1:160 58 (95)
8 33 (72) 1:20 60 (98)
9 7 (15) Unknown 51 (84)
10 11 (24) 1:0 61 (100)
11 11 (24) 1:5 61 (100)
12 26 (57) 1:10 60 (98)
* No. (%) reactive among 46 positive sera (29 known positive sera and 17 blood donor sera previously reactive by at least 2 assays [tests 1, 6, and 7]).
dagger Early convalescent human serum diluted with normal human serum.
Dagger No. (%) nonreactive among 61 negative sera (22 known negative sera and 39 blood donor sera previously nonreactive by at least 2 assays [tests 1, 6, and 7]).

Return To Article

Copyright © 1998 by the American Association for the Study of Liver Diseases.
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 07 Oct 2008